> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# RSV vaccines show positive pooled net benefit in older adults, uncertain for maternal use
- URL: https://www.coios.me/rsv-vaccines-show-positive-pooled-net-benefit-in-older/
- Published: 2026-11-18T13:08:28.000Z
- Updated: 2026-11-18T13:57:33.000Z
- Description: Across 11 cost-effectiveness studies, RSV vaccination's pooled net benefit was USD 105 in older adults and USD 6 in infants.
- Author: Daniel Ryan
- Tags: Data, models and systems, Value in health, Infection and pandemics, World, #peer-reviewed, #refines, #item, #source-2026-11, #score-68

This meta-analysis pooled the incremental net benefit (INB) of marketed RSV vaccines against no vaccination. Of 17 model-based evaluations, all from high-income settings, 11 entered random-effects meta-analyses run separately by population. In older adults the pooled INB was USD 105.05 (95% CI 41.89–168.21). It stayed positive when any one study was left out. For infants, via maternal vaccination, it was USD 5.81 (95% CI −35.44 to 47.07), sensitive to study exclusion. Heterogeneity was high (I² 93.2% and 89.4%), and no study came from low- or middle-income countries.

*Why it is interesting: Pooling net benefit rather than cost-effectiveness ratios lets economic evaluations be combined on one monetary scale. Among older adults, strategies targeting older ages or higher-risk groups gave higher net benefit than broad age-based programmes.*

Source

[Infectious Diseases of Poverty, 14 November 2026](https://doi.org/10.1186/s40249-026-01520-y?ref=coios.me)

DOI

10.1186/s40249-026-01520-y

Full text

[Open copy](https://pmc.ncbi.nlm.nih.gov/articles/PMC13770325/?ref=coios.me) (open-access copy, PubMed Central)

Type

Peer-reviewed article

Design

Systematic review and random-effects meta-analysis of incremental net benefit from 17 post-marketing RSV vaccine economic evaluations (11 in primary meta-analysis), searched to November 2025

Verdict

Refines prior evidence

Driver

[Value in health](https://www.coios.me/d-health-economics/)

Driver

[Infection and pandemics](https://www.coios.me/d-infectious-disease/)